AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
NSE · Healthcare · Mid Cap · Mkt cap ₹902.0B · Vol 9.57M
₹7,404.69
▲ +0.99% today
Fetching live price…
God's Eye forensics
Accounting quality and solvency screens. Anything that can't be computed from available filings data is left blank rather than estimated.
Piotroski F-Score
5/55
5 of 5 financial-health checks passed (4 checks need data this provider doesn't publish).
Altman Z-Score
Insufficient data—
Needs total assets, operating profit and debt — not published for this listing yet.
Beneish (earnings quality)
Insufficient data—
The full manipulation model needs two years of receivables, depreciation and accrual data, which isn't published for this listing.
Scores are free. The criteria-by-criteria breakdown — exactly which checks this company failed — is part of DeepScreen Pro.
Fundamental breakdown — raw ratios are free · fetching live data — showing modeled estimates for now
P/E Ratio (TTM)
Modeled26.3x
Fairly priced
Contextual insight — DeepScreen Pro
PEG Ratio
Modeled2.14
Overvalued vs. growth
Contextual insight — DeepScreen Pro
P/S Ratio
Modeled6.21x
Rich sales multiple
Contextual insight — DeepScreen Pro
P/B Ratio
Modeled7.50x
Typical for the sector
Contextual insight — DeepScreen Pro
EV/Revenue
Modeled4.00x
Typical for the sector
Contextual insight — DeepScreen Pro
EV/EBITDA
Modeled13.7x
Low for asset-light
Contextual insight — DeepScreen Pro
ROE
Modeled28.5%
Excellent shareholder returns
Contextual insight — DeepScreen Pro
ROA
Modeled13.4%
Adequate
Contextual insight — DeepScreen Pro
ROCE
Modeled16.9%
Solid
Contextual insight — DeepScreen Pro
Debt / Equity
Modeled0.78x
Manageable
Contextual insight — DeepScreen Pro
LT Debt / Equity
Modeled0.41x
Moderate long-term leverage
Contextual insight — DeepScreen Pro
Payout Ratio
Modeled31%
Ideal balance — sustainable with room to reinvest
Contextual insight — DeepScreen Pro
Operating Leverage
Modeled1.30x
Low fixed-cost gearing
Contextual insight — DeepScreen Pro
Company financials
- EPS (TTM)
- ₹281.55
- Revenue (TTM)
- ₹145.2B
- Net margin
- 23.6%
- EBITDA margin
- 29.2%
- Earnings growth
- 12.3%
- Dividend yield
- 1.18%
- Payout ratio
- 31%
- Debt / equity
- 0.78x
Live data hasn't loaded yet — figures shown are DeepScreen's modeled estimates.
AAREYDRUGS live news
LIVELoading live headlines…